Health TrialsbyHealthPanel

Relationship Between FGF19 Overexpression and Disease Prognosis

ConditionHepatocellular Carcinoma (HCC)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Tsinghua Chang Gung Hospital

About this trial

A real-world study of FGF19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years on the day of signing the informed consent form

Histologically or clinically confirmed diagnosis of intermediate to advanced HCC

Adequate tissue samples of previous liver cancer

Expected survival of more than 3 months

Disqualifiers

Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes

Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate

Trial population

Patients with HCC in the middle to late stages of the disease；Sufficient previous hepatocellular carcinoma tissue samples were available for immunohistochemical detection of FGF19

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Other intervention

    This is an observational study and does not involve an intervention

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: inspection team0 interventions

Trial outcomes

Primary outcomes

1

PFS

PFS was calculated from the date of randomization to the date of the first documented disease progression, with no time constraints involved, marked by the appearance of disease progression

Time frame
Enrollment until disease progression
2

OS

Observation until death from the beginning of participation in the study observation until death from any cause, no time frame limitations were involved. Calculation of OS based on time of death

Time frame
Start of enrollment until death (from any cause)

Secondary outcomes

1

ORR

Proportion of patients whose tumor volume shrinks to a preset value and remains unchanged for a given period of time, total study duration 36 months, ORR observation period within 36 months

Time frame
Time to enrollment until disease downsizing

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beijing Tsinghua Chang Gung Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: